NO995006L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO995006L
NO995006L NO995006A NO995006A NO995006L NO 995006 L NO995006 L NO 995006L NO 995006 A NO995006 A NO 995006A NO 995006 A NO995006 A NO 995006A NO 995006 L NO995006 L NO 995006L
Authority
NO
Norway
Prior art keywords
new connections
compounds
processes
formula
preparation
Prior art date
Application number
NO995006A
Other languages
English (en)
Other versions
NO995006D0 (no
Inventor
David Cheshire
Martin Cooper
David Donald
Philip Thorne
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of NO995006D0 publication Critical patent/NO995006D0/no
Publication of NO995006L publication Critical patent/NO995006L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Farmasøytisk nyttige pyra2o]o[3,4-d]pyrimidindionforbindelser av formel (I) w / N-R (D fremgangsmåter for deres fremstilling, farmasøytiske preparater inneholdende slike forbindelser, og deres anvendelse for behandling av forskjellige sykdommer.
NO995006A 1997-04-15 1999-10-14 Nye forbindelser NO995006L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9701398A SE9701398D0 (sv) 1997-04-15 1997-04-15 Novel compounds
PCT/SE1998/000640 WO1998046606A1 (en) 1997-04-15 1998-04-07 Novel compounds

Publications (2)

Publication Number Publication Date
NO995006D0 NO995006D0 (no) 1999-10-14
NO995006L true NO995006L (no) 1999-10-14

Family

ID=20406576

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995006A NO995006L (no) 1997-04-15 1999-10-14 Nye forbindelser

Country Status (21)

Country Link
US (1) US6028074A (no)
EP (1) EP0975636B1 (no)
JP (1) JP2001520645A (no)
KR (1) KR20010006350A (no)
CN (1) CN1259951A (no)
AT (1) ATE245648T1 (no)
AU (1) AU733066B2 (no)
BR (1) BR9808540A (no)
CA (1) CA2286078A1 (no)
DE (1) DE69816608T2 (no)
EE (1) EE9900465A (no)
HU (1) HUP0002104A3 (no)
ID (1) ID22746A (no)
IL (1) IL132153A0 (no)
IS (1) IS5198A (no)
NO (1) NO995006L (no)
PL (1) PL336230A1 (no)
SE (1) SE9701398D0 (no)
SK (1) SK135699A3 (no)
TR (1) TR199902538T2 (no)
WO (1) WO1998046606A1 (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6875786B2 (en) 2001-03-01 2005-04-05 Smithkline Beecham Corporation Thrombopoietin mimetics
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
AR040083A1 (es) 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
EP1901701A4 (en) * 2005-05-24 2012-05-02 David M Ott BODY CARE AND MEDICAL PRODUCTS WITH JOINED SULFUR ORGANIC GROUPS
CN103467471A (zh) 2005-06-06 2013-12-25 武田药品工业株式会社 有机化合物
AU2007256633B2 (en) * 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
EP2081431B1 (en) 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
MX2010006208A (es) * 2007-12-06 2010-12-21 Intra Cellular Therapies Inc Compuestos organicos.
CN104370919A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
SG171776A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
JP5778582B2 (ja) 2008-12-06 2015-09-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EA201170769A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
US8697710B2 (en) 2008-12-06 2014-04-15 Intra-Cellular Therapies, Inc. Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones
MA32939B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
EA201170772A1 (ru) * 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
EP2400970A4 (en) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE 1 INHIBITOR FOR OPHTHALMIC DISORDERS
ES2551085T3 (es) * 2009-03-23 2015-11-16 Glenmark Pharmaceuticals S.A. Proceso para preparar derivados de pirimidina-diona condensados, útiles como moduladores de TRPA1
AU2010227225A1 (en) 2009-03-23 2011-09-15 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as TRPA1 modulators
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
SG174403A1 (en) 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
EP2434895A4 (en) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
CN104173337A (zh) 2009-05-29 2014-12-03 葛兰素史密斯克莱有限责任公司 给药血小板生成素激动剂化合物的方法
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc ORGANIC COMPOUNDS
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
US9458173B2 (en) 2012-06-08 2016-10-04 Glenmark Pharmaceuticals S.A. Amides of 2-amino-4-arylthiazole compounds and their salts
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
CN105377846B (zh) 2013-03-15 2018-03-20 细胞内治疗公司 有机化合物
ES2717688T3 (es) 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
EP3157926B1 (en) 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Organic compounds
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
EP3193878B1 (en) 2014-09-17 2021-01-06 Intra-Cellular Therapies, Inc. 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns)
CN107205993B (zh) 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
JP6608934B2 (ja) 2014-12-06 2019-11-20 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
CN109311886B (zh) * 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]***并[4,5-d]嘧啶衍生物
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
WO2019152697A1 (en) 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Novel uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0063381A1 (de) * 1981-04-22 1982-10-27 Byk Gulden Lomberg Chemische Fabrik GmbH Neue Pyrazolo(3,4-d)pyrimidine, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
US4603203A (en) * 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
EP0237289A3 (en) * 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
DK0674624T3 (da) * 1992-12-17 1999-09-13 Pfizer Pyrazoler med CRF-antagonistisk aktivitet
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines

Also Published As

Publication number Publication date
PL336230A1 (en) 2000-06-19
HUP0002104A2 (hu) 2001-01-29
IL132153A0 (en) 2001-03-19
BR9808540A (pt) 2000-05-23
WO1998046606A1 (en) 1998-10-22
JP2001520645A (ja) 2001-10-30
EP0975636B1 (en) 2003-07-23
SK135699A3 (en) 2000-05-16
IS5198A (is) 1999-09-27
HUP0002104A3 (en) 2002-03-28
US6028074A (en) 2000-02-22
NO995006D0 (no) 1999-10-14
DE69816608T2 (de) 2004-04-15
DE69816608D1 (de) 2003-08-28
ATE245648T1 (de) 2003-08-15
ID22746A (id) 1999-12-09
CA2286078A1 (en) 1998-10-22
TR199902538T2 (xx) 2000-02-21
AU7090998A (en) 1998-11-11
EE9900465A (et) 2000-04-17
SE9701398D0 (sv) 1997-04-15
CN1259951A (zh) 2000-07-12
AU733066B2 (en) 2001-05-03
KR20010006350A (ko) 2001-01-26
EP0975636A1 (en) 2000-02-02

Similar Documents

Publication Publication Date Title
NO995006L (no) Nye forbindelser
NO20000311L (no) Nye forbindelser
NO20000313L (no) Nye forbindelser
NO993027L (no) Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler
SE9702001D0 (sv) Novel compounds
GR3023825T3 (en) Benzopyran derivatives, processes for their preparation and their use and preparations containing the compounds
CA2263561A1 (en) Thienopyrimidines
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
NO20002788D0 (no) Nye forbindelser
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
CA2216535A1 (en) Protein kinase c inhibitors
NO904694L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
CA2181175A1 (en) Dihydro Pyrazolopyrroles
CA2137203A1 (en) Protein kinase c inhibitors
NO882732D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO901684L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO903088L (no) Fremgangsmaate for fremstilling av terapeutisk aktive diazepin-derivater.
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
NO172537C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-desmetyl-4-fluor-mevalonsyrederivater
NO167028C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrazolo(3,4-d)pyrimidinderivater
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
NO900972D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO165544C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktivt 2,3-dihydro-1-(8-methyl-1,2,4-triazolo-(4,3-b)pyridazin-6-yl)-4(1h)-pyridinon.
FI933872A (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3,4-bensotriazepin-5(4H)-on-derivat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application